Kazuaki Shinoda
Yokohama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.
Journal: Endocrine journal
Published: June 20, 2020
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Journal: Journal of diabetes investigation
Published: December 06, 2019
Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: May 25, 2017
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Journal: Journal of clinical medicine research
Published: April 11, 2017
Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
Journal: Internal medicine (Tokyo, Japan)
Published: July 05, 2016
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: January 20, 2016
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: November 24, 2015
Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus.
Journal: The Journal of international medical research
Published: July 13, 2014
Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
Journal: Journal of clinical pharmacology
Published: June 29, 2014
Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
Journal: Expert opinion on pharmacotherapy
Published: April 23, 2013
Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
Journal: Endocrinology
Published: February 09, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026